In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss

The FDA has approved Wegovy HD, a 7.2-mg dose of the injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, for use in adults who have tolerated the 2.4-mg dose for at least 4 weeks and require additional weight reduction.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2026-05-11
DOI
https://doi.org/10.58347/tml.2026.1754c
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss

˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Diabetes Treatment and Management
article

In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss

article en

Abstract

The FDA has approved Wegovy HD, a 7.2-mg dose of the injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, for use in adults who have tolerated the 2.4-mg dose for at least 4 weeks and require additional weight reduction.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 68(1754)
Zero hunger
Openalex Percentile: Top 17%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.